Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel polymer micelle-based chemotherapy for previously treated metastatic pancreatic cancer
ChiCTR2600131381Phase 2Not yet recruiting
- Sponsor
- Hangzhou First People's Hospital
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of paclitaxel and gemcitabine in pancreatic adenocarcinoma (PDAC) and pancreatic cancer (PDAC) (2 cohorts), sponsored by Hangzhou First People's Hospital. Primary endpoints: overall survival and progression-free survival. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
paclitaxelgemcitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)pancreatic cancer (PDAC)
Beyond the preview
Go deeper on ChiCTR2600131381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600131381.